Bertrand Lellouche has stepped down from his position of Promethera® Group Chief Financial Officer (“CFO”).
A new executive committee has been installed to ensure the continuity and to implement the strategy of the company going forward. Three board members, Zimeng Dong, Alain Parthoens, and Etienne Sokal have been appointed to an executive committee which will collectively exercise the function of CEO.
Charles L. Dimmler III, has resigned from his position of Chairman of the Board of Directors. Prof. Etienne Sokal, MD, PhD, founder of Promethera® and board member, has been elected as Chairman of the board, with effect on September 1st, 2020.
“The new management and the Board of Directors are committed to pursue the development of Promethera® for the best interest of patients, employees and shareholders. Together we strongly believe in the capacity of HepaStem™ as a lifesaving treatment for patients with severe loss of liver function, who would otherwise require liver transplantation.” said Prof. Etienne Sokal.
ABOUT PROMETHERA® BIOSCIENCES (PROMETHERA® GROUP)
Watson & Crick Hill - Rue Granbonpré 11, 1435 Mont-Saint-Guibert, Belgique
Promethera® Biosciences is a global innovator in liver therapeutics whose mission is to bring patients life-saving treatments to reduce the need for liver transplantation. Promethera® develops and manufactures allogeneic cell-based medicines for liver diseases by using regenerative medicine technology.
Global Senior Director Communications
Contact Information for Medias:
MARIO BRKULJ - +49 89 2420 9345
SHAI BIRAN, Ph.D. - +1 781-235-3060